Marc Bourlière Selected Research

faldaprevir

5/2016	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
6/2015	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
2/2015	Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
1/2015	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
8/2013	Faldaprevir and deleobuvir for HCV genotype 1 infection.
6/2013	Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
6/2011	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Bourlière Research Topics

Disease

39	Infections 10/2022 - 05/2002
31	Fibrosis (Cirrhosis) 10/2022 - 12/2006
30	Chronic Hepatitis C 10/2021 - 05/2002
12	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 08/2007
12	Hepatitis C 06/2019 - 10/2006
10	Liver Cirrhosis (Hepatic Cirrhosis) 10/2022 - 07/2005
9	Neoplasms (Cancer) 11/2021 - 04/2016
8	Liver Diseases (Liver Disease) 10/2022 - 12/2006
6	Chronic Hepatitis B 10/2022 - 10/2006
4	Liver Neoplasms (Liver Cancer) 08/2020 - 04/2016
4	Anemia 01/2016 - 04/2009
3	Autoimmune Hepatitis 01/2022 - 04/2006
3	Coinfection 01/2019 - 01/2006
3	Neutropenia 01/2018 - 01/2013
2	Portal Hypertension 10/2022 - 04/2015
2	Hypertension (High Blood Pressure) 02/2022 - 01/2018
2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 04/2006
2	Chronic Renal Insufficiency 01/2022 - 01/2018
2	Disease Progression 01/2021 - 11/2019
2	Inflammation (Inflammations) 04/2015 - 12/2006
2	Virus Diseases (Viral Diseases) 02/2015 - 02/2006
2	Pruritus (Itching) 02/2012 - 04/2009
2	Exanthema (Rash) 02/2012 - 04/2009
2	Chronic Hepatitis (Chronic Active Hepatitis) 08/2007 - 04/2006
1	Ascites 10/2022
1	Dyslipidemias (Dyslipidemia) 02/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Iron Overload 01/2022
1	Cholestasis 01/2022
1	Sclerosing Cholangitis 01/2022
1	End Stage Liver Disease 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2022
1	Focal Nodular Hyperplasia 01/2022
1	Cholangitis 01/2022
1	HIV Infections (HIV Infection) 11/2021
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2019
1	Diabetes Mellitus 01/2018
1	Thrombocytopenia 4 01/2018
1	Viremia 01/2018
1	Leukopenia 01/2018
1	Pulmonary Embolism 01/2017
1	Syncope (Fainting) 01/2017

Drug/Important Bio-Agent (IBA)

34	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 05/2002
29	Antiviral Agents (Antivirals)IBA 06/2022 - 02/2006
24	InterferonsIBA 11/2018 - 05/2002
10	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 06/2011
9	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 03/2016 - 02/2012
9	RNA (Ribonucleic Acid)IBA 03/2016 - 01/2006
9	telaprevirIBA 01/2016 - 04/2009
7	SofosbuvirIBA 01/2022 - 01/2015
7	faldaprevirIBA 05/2016 - 06/2011
5	daclatasvirIBA 01/2018 - 02/2014
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 08/2020 - 06/2017
4	peginterferon alfa-2a (Pegasys)FDA Link 01/2017 - 10/2006
4	deleobuvirIBA 02/2015 - 08/2013
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2022 - 01/2017
3	Biological ProductsIBA 10/2022 - 01/2022
3	Coffee FDA Link 06/2022 - 01/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 02/2012
3	ledipasvirIBA 01/2017 - 01/2015
3	sofosbuvir drug combination ledipasvirIBA 01/2017 - 04/2015
3	peginterferon alfa-2b (Pegintron)FDA Link 01/2013 - 02/2007
2	AutoantibodiesIBA 01/2022 - 01/2022
2	BilirubinIBA 08/2020 - 01/2018
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2019 - 01/2009
2	grazoprevirIBA 01/2018 - 01/2017
2	TabletsIBA 01/2018 - 01/2015
2	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2018 - 01/2017
2	elbasvirIBA 01/2018 - 01/2017
2	velpatasvirIBA 01/2017 - 12/2015
2	Hemoglobins (Hemoglobin)IBA 01/2017 - 01/2013
2	AntigensIBA 01/2017 - 12/2006
2	N- (8- aminohexyl)- 5- iodonaphthalene- 1- sulfonamide (W8)IBA 03/2016 - 01/2016
2	Inosine TriphosphataseIBA 01/2016 - 01/2015
2	NucleosidesIBA 01/2015 - 02/2014
2	asunaprevirIBA 02/2014 - 01/2013
2	InterleukinsIBA 02/2014 - 01/2012
2	Erythropoietin FDA Link 09/2013 - 08/2007
2	Biomarkers (Surrogate Marker)IBA 03/2007 - 07/2005
1	CannabinoidsIBA 10/2022
1	4-(3-chlorophenylsulfanyl)piperidineIBA 10/2022
1	Contrast MediaIBA 01/2022
1	Ferritins (Ferritin)IBA 01/2022
1	AlbuminsIBA 08/2020
1	Ethiodized Oil (Ethiodol)FDA Link 11/2019
1	Sorafenib (BAY 43-9006)FDA Link 11/2019
1	Transaminases (Aminotransferases)IBA 01/2018
1	glecaprevirIBA 01/2018
1	pibrentasvirIBA 01/2018
1	glecaprevir and pibrentasvirIBA 01/2018
1	omega-Chloroacetophenone (Mace)IBA 01/2018
1	Serum AlbuminIBA 01/2018
1	CreatinineIBA 01/2017

Therapy/Procedure

32	Therapeutics 01/2022 - 05/2002
4	Retreatment 01/2018 - 04/2007
3	Liver Transplantation 10/2022 - 01/2021
3	Duration of Therapy 11/2019 - 05/2002
2	Transplantation 01/2020 - 01/2018
1	Renal Dialysis (Hemodialysis) 01/2018
1	Surgical Instruments (Clip) 04/2017